Treatment of Non bleeding piles with Unani Medicine Habb-e-Bawaseer Amya.

Clinical Validation of Unani Pharmacopoeal formulation Habb-e-Bawaseer Amya in Bawaseer Amya (Non bleeding piles)

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2018/08/015373

Enrollment

300

Registered

2018-08-17

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Bawaseer Amya (Non bleeding piles) Health Condition 2: K640- First degree hemorrhoids

Interventions

Intervention1: Habb-e-Bawaseer Umiyya: Habb-e-Bawaseer Umiyya, 1 Pill (250 mg ) orally Twice daily with water one hour after meals for two weeks Control Intervention1: Nil: Nil

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients of either sex in the age group 18 to 65 years 2. Patients diagnosed with BawÄ?sÄ«r Umiyya (Non-bleeding Piles) presenting with any of the following symptoms: (i) Mucoid Anal/ Perianal Discharge (SayalÄ?n al-Maqâ??ad MukhÄ?tÄ«): mucus discharge (ii) Pruritus Ani (Hikka al-Maqâ??ad) (iii) Mucosal Prolapse (KhurÅ«j al-MukhÄ?tÄ«yya) with Spontaneous Reduction (iv) Rectal/ Anal Pain (Wajaâ?? al-Maqâ??ad)

Exclusion criteria

Exclusion criteria: The following patients will be excluded from the study: 1. Patients with Bawaseer Damiya (Bleeding piles). 2. Patients with Fourth Degree Haemorrhoids (irreducible prolapse) 3. Known cases of Anal fissure, anal fistula and other surgical conditions of the anus. 4. Known cases of other clinically significant co-morbid conditions (severe hepatic, renal, cardiovascular disorders, etc) 5. Patients with Inflammatory Bowel Disorders (Positive Haemoccult Test) 6. Pregnant and Lactating Women

Design outcomes

Primary

Measure	Time frame
Improvement in signs and symptoms of Bawaseer Amya (Non bleeding piles)Timepoint: Two Weeks	—

Secondary

Measure	Time frame
Haematological and biochemical assessment for safety assessmentTimepoint: Two weeks	—

Countries

India

Contacts

Public ContactDr Pradeep Kumar

Central Council for Research in Unani Medicine (CCRUM)

ccrum507@rediffmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026